Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 1/20 | 0.72 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | EGFR | P00533 | 11/20 | 0.64 |
| ▸ | KRAS | P01116 | 1/20 | 0.64 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.64 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31505701 | 1.00 | GALR3 (0.72) | GALR3NR2F2LMNAHTTSMN1; SMN2 | |
| SCHEMBL31505705 | 1.00 | GALR3 (0.72) | GALR3NR2F2LMNAHTTSMN1; SMN2 | |
| SCHEMBL644489 | 0.85 | GALR3 (0.70) | GALR3NR2F2LMNAEGFRKRAS | |
| SCHEMBL9921344 | 0.85 | GALR3 (0.70) | GALR3NR2F2LMNAEGFRKRAS | |
| SCHEMBL31505709 | 0.85 | GALR3 (0.70) | GALR3NR2F2LMNAEGFRKRAS | |
| SCHEMBL24577013 | 0.85 | GALR3 (0.70) | GALR3NR2F2LMNAEGFRKRAS | |
| SCHEMBL13170943 | 0.85 | GALR3 (0.70) | GALR3NR2F2LMNAEGFRKRAS | |
| SCHEMBL24576524 | 0.85 | GALR3 (0.70) | GALR3NR2F2LMNAEGFRKRAS | |
| SCHEMBL6992336 | 0.85 | GALR3 (0.70) | GALR3NR2F2LMNAEGFRKRAS | |
| SCHEMBL29775126 | 0.85 | GALR3 (0.70) | GALR3NR2F2LMNAEGFRKRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101914-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS HAVING IMPROVED THERAPEUTIC INDEX AGAINST SOLID TUMORS | MEKANISTIC THERAPEUTICS LLC (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| US-20240083868-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | MEKANISTIC THERAPEUTICS, LLC | 2024-03-14 | — | — | US | disclosed |
| EP-4267554-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | Mekanistic Therapeutics LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | MEKANISTIC THERAPEUTICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | MEKANISTIC THERAPEUTICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | MEKANISTIC THERAPEUTICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220213054-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | MEKANISTIC THERAPEUTICS LLC (US) | 2022-07-07 | — | — | US | disclosed |
| WO-2022140456-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | MEKANISTIC THERAPEUTICS LLC (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140456-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | MEKANISTIC THERAPEUTICS LLC (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20100190807-A1 | CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein | SENEX BIOTECHNOLOGY, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20090281129-A1 | CDKI PATHWAY INHIBITORS AND USES THEREOF | SENEX BIOTECHNOLOGY, INC. | 2009-11-12 | — | — | US | disclosed |
| US-20080033000-A1 | Identification of CDKI pathway inhibitors | SENEX BIOTECHNOLOGY, INC. | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | GALR3 2838/4885NR2F2 1965/4885LMNA 3609/4885 |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | EGFR, ERBB2, ERBB3 | GALR3 2838/4885NR2F2 1965/4885LMNA 3609/4885 |
| US-20220213054-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | GALR3 2838/4885NR2F2 1965/4885LMNA 3609/4885 |
| US-20100190807-A1 | CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein | MAPT, CDK5, CDKN1A | GALR3 3687/4885NR2F2 1129/4885LMNA 2105/4885 |
| US-20090281129-A1 | CDKI PATHWAY INHIBITORS AND USES THEREOF | CDKN1A, CDK6, CCNI | GALR3 3753/4885NR2F2 1164/4885LMNA 1622/4885 |
| US-20240083868-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | GALR3 2838/4885NR2F2 1965/4885LMNA 3609/4885 |
| US-20080033000-A1 | Identification of CDKI pathway inhibitors | CDKN1A, CDK6, CDK2 | GALR3 3564/4885NR2F2 850/4885LMNA 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.